Richard Dolinar, MD
Endocrinology · Phoenix, AZNPI 1548227028
Payments from drug & device makers
Across 759 payments — averaging $541.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$343K
- Novo Nordisk$37K
- Boehringer Ingelheim$17K
- AstraZeneca$7K
- Medtronic$2K
- Tandem Diabetes Care, Inc.$2K
- plus $4K from 17 others
What the payments were for
- Consulting fees$6,8852%
- Speaking & faculty fees$368,48890%
- Travel & lodging$24,6976%
- Food & beverage$10,7193%
- Education$1920%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 510 | $342,888 |
| Novo Nordisk | 44 | $36,664 |
| Boehringer Ingelheim | 27 | $17,329 |
| AstraZeneca | 16 | $6,555 |
| Medtronic | 16 | $1,874 |
| Tandem Diabetes Care, Inc. | 5 | $1,500 |
| Sanofi-aventis U.S. LLC | 21 | $1,084 |
| Insulet Corporation | 46 | $943 |
| Abbott | 37 | $708 |
| Amgen | 15 | $648 |
| Bayer | 2 | $210 |
| Johnson & Johnson | 3 | $139 |
| AbbVie | 1 | $90 |
| Gilead | 1 | $83 |
| Mannkind Corporation | 2 | $74 |
| Radius Health, Inc. | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Amneal Pharmaceuticals LLC | 2 | $41 |
| Dexcom, Inc. | 2 | $37 |
| Corcept Therapeutics | 1 | $27 |
| Verity Pharmaceuticals Inc. | 1 | $21 |
| Nevro Corp. | 1 | $17 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$116,290
- TRULICITY$115,045
- JARDIANCE$73,847
- Ozempic$21,041
- Tresiba$10,978
- FARXIGA$6,010
- RYBELSUS$1,580
- Victoza$1,485
- MINIMED 780G$1,286
- t:slim X2 insulin pump$1,200
- TZIELD$518
- t-slim insulin pump$300
- Repatha$250
- Kerendia$210
- FREESTYLE LIBRE 3$141
- Omnipod$134
- INVOKANA$125
- PRALUENT$121
- LOKELMA$121
- SOLIQUA 100/33$116
How this compares
Too few endocrinology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 280 | $420,212 |
| TrulicityDulaglutide | 257 | $408,523 |
| JardianceEmpagliflozin | 269 | $353,560 |
| MounjaroTirzepatide | 191 | $280,585 |
| FarxigaDapagliflozin Propanediol | 94 | $102,637 |
| Tresiba Flextouch U-100Insulin Degludec | 98 | $56,234 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $32,407 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $27,212 |
| Humalog Kwikpen U-100Insulin Lispro | 102 | $25,440 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 135 | $21,900 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 130 | $21,695 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $16,820 |
| LyumjevInsulin Lispro-Aabc | 11 | $16,568 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 15 | $15,929 |
| Novolog FlexpenInsulin Aspart | 58 | $15,914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev, Baqsimi, Humalog | $342,888 | $718,472491 claims |
| Novo NordiskOzempic | $36,664 | $420,212280 claims |
| Boehringer IngelheimJardiance | $17,329 | $353,560269 claims |
| AstraZenecaFarxiga | $6,555 | $102,63794 claims |
| AbbVieSynthroid | $90 | $8,45761 claims |
| Sanofi-aventis U.S. LLCLantus | $1,084 | $5,03315 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $41 | $1,517134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Phoenix
- Chet MonderPhoenix$5K
- Radhika VattikutiPhoenix$2K
- Stefan HasinskiPhoenix$1K
- Cristian SciuttoPhoenix$0
- Rohit DwivediSurprise$91K
- Mohamad HoraniChandler$0
- Sapna ShahTucson$0
- Freeman FavorsGlendale$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.